COLLEGIUM PHARMACEUTICAL, INC Material Event - What Happened

Hey there! Let's break down some important news from COLLEGIUM PHARMACEUTICAL, INC (you might see their stock ticker as COLL). Think of this as me explaining it to you over coffee, not some stuffy financial report.

1. What happened? (in plain English - the actual event)

Big news from COLLEGIUM! They will buy a new drug called AZSTARYS®. This prescription medicine treats Attention Deficit Hyperactivity Disorder (ADHD). It is for patients aged six years and older. AZSTARYS® is a once-daily stimulant. It offers a unique profile in the ADHD market. COLLEGIUM will acquire U.S. rights to AZSTARYS® from Corium Therapeutics Holdings, LLC and Corium, LLC. COLLEGIUM will pay $650 million cash. They may pay an extra $135 million later. This depends on AZSTARYS® reaching sales or regulatory goals. COLLEGIUM is growing its business. They add a new product in ADHD. This moves them beyond pain medications like XTAMPZA® ER and NUCYNTA® ER/IR.

2. When did it happen?

COLLEGIUM signed the deal for AZSTARYS® on March 19, 2026. They expect the deal to close in Q2 2026. This needs standard approvals. It also requires clearance under the Hart-Scott-Rodino Act.

3. Why did it happen? (context and background)

COLLEGIUM wants to grow and diversify. They are known for pain medications like XTAMPZA® ER and NUCYNTA® ER/IR. Buying AZSTARYS® lets them enter the ADHD market. This move brings new income. It expands their reach beyond current products. The ADHD market is large, over $10 billion yearly. It offers strong growth potential. AZSTARYS® sold about $88 million in 2023. This shows its established market presence. COLLEGIUM wants an established, growing product. AZSTARYS® has patent protection until 2037. This lets them quickly enter a profitable market. They avoid years developing a new drug. This purchase will use COLLEGIUM's sales network. It should immediately boost their financial results.

4. Why does this matter? (impact and significance)

So, why does this matter? This is a big deal for COLLEGIUM.

• New Market, New Growth: COLLEGIUM enters the big ADHD market. This means new customers and future sales. It can boost company growth. AZSTARYS® should add $105-$115 million in sales in 2026. This assumes a Q2 2026 close. It should immediately boost COLLEGIUM's adjusted profit and earnings per share.
• Big Investment: Spending $650 million (plus potential extra payments) shows COLLEGIUM's commitment. They believe AZSTARYS® has strong potential. This is a big financial commitment. They fund it with cash and new loans. This investment should boost COLLEGIUM's income and profit.
• Diversification: COLLEGIUM now spreads its focus. They move beyond just pain relief medications. This makes the company more stable. It reduces risks from issues in one market. This is key as opioid rules change.
• Company Value: Successful purchases and new markets often raise company value. This is good news for shareholders. This move should strengthen COLLEGIUM's long-term growth and market position.

5. Who is affected? (employees, customers, investors, etc.)

This news affects several groups:

• COLLEGIUM Employees: This could mean new opportunities and teams. It may boost morale as the company expands. It might also include Corium's AZSTARYS® sales team.
• COLLEGIUM Investors (that's you!): The stock price might react. This shows investor confidence or concern. They will weigh the deal's fit, cost, and integration. It points to a new direction and future earnings. Key financial numbers should see a positive impact.
• ADHD Patients: They might see more marketing or availability of AZSTARYS®. COLLEGIUM will handle its promotion and distribution. Patients could benefit from COLLEGIUM's sales expertise.
• Doctors: They will have another ADHD treatment option. COLLEGIUM, a strong specialty drug company, now backs it.
• Competitors in the ADHD Market: Other drug companies sell ADHD medicines. These include Takeda (Vyvanse), Johnson & Johnson (Concerta), and Noven (Daytrana). They now face COLLEGIUM as a new, aggressive player. This could increase market competition.
• The Sellers (Corium Therapeutics Holdings, LLC and Corium, LLC): They get a large cash payment. They previously sold AZSTARYS®.

6. What happens next? (immediate and future implications)

What happens next?

• Closing the Deal: First, they must finalize the purchase. This needs all regulatory approvals. It includes clearance from the Hart-Scott-Rodino Act. This should happen by Q2 2026.
• Integration: After closing, COLLEGIUM will integrate AZSTARYS® into its business. This means taking over making, selling, marketing, and distributing the drug. COLLEGIUM will use its sales network. They will integrate the AZSTARYS® sales team. This ensures a smooth transition and boosts market reach.
• Performance-Based Payments: COLLEGIUM wants AZSTARYS® to perform well. Reaching sales goals in 2027 and 2028 could trigger $135 million extra payments. These go to the sellers.
• Market Strategy: COLLEGIUM will create a strong plan. They will grow AZSTARYS®'s market share in ADHD. They will focus on its unique profile. They will expand reach to doctors and patients.

7. What should investors/traders know? (practical takeaways)

Alright, for investors and traders, here's what to know:

• Stock Reaction: Purchases can affect stock prices in different ways. Sometimes the market likes growth potential. Sometimes it worries about cost or integration. Watch how COLL's stock reacts. Pay attention to the closing news and early sales.
• Financial Impact: This is a big cash expense for COLLEGIUM. It promises future income. It should immediately boost adjusted profit and earnings per share. But it impacts their cash and raises their debt. The company expects its debt-to-profit ratio to be about 3.0x to 3.5x after the purchase.
• Not a Done Deal (Yet): The agreement is signed. But the purchase still needs to close. It also needs regulatory approval. It might fall through. If so, COLLEGIUM could pay a $24 million termination fee. This depends on specific reasons.
• Long-Term Play: This purchase is a long-term growth plan. It will take time to see AZSTARYS®'s full financial benefits. Investors should watch its sales and market share for quarters.
• Risks to Consider: Beyond the termination fee, risks exist. These include integration challenges. There is also strong ADHD market competition. Sales could be lower than expected. Generic competition for ADHD drugs is a broader risk. This is true despite AZSTARYS®'s patent until 2037.
• Keep an Eye Out: Watch for news on the deal's closing. Look for updates on AZSTARYS® sales or strategy. Check COLLEGIUM's quarterly calls and presentations.
• Do Your Own Homework: This summary is a good start. Always check details yourself. Or talk to a financial advisor. Do this before making any investment decisions. Good luck!